IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v35y2017i1d10.1007_s40273-017-0550-0.html
   My bibliography  Save this article

The Use of Health State Utility Values in Decision Models

Author

Listed:
  • Roberta Ara

    (University of Sheffield)

  • John Brazier

    (University of Sheffield)

  • Ismail Azzabi Zouraq

    (Takeda Pharmaceuticals International AG)

Abstract

Methodological issues of how to use health state utility values (HSUVs) in decision models arise frequently, including the most appropriate evidence to use as the baseline (e.g. the baseline HSUVs associated with avoiding a particular health condition or event), how to capture changes due to adverse events and how to appropriately capture uncertainty in progressive conditions where the expected change in quality of life is likely to be monotonically decreasing over time. As preference-based measures provide different values when collected from the same patient, it is important to ensure that all HSUVs used within a single model are obtained from the same instrument where ever possible. When people enter the model without the condition of interest (e.g. primary prevention of cardiovascular disease, screening or vaccination programmes), appropriate age- and gender-adjusted HSUVs from people without the particular condition should be used as the baseline. General population norms may be used as a proxy if the exact condition-specific evidence is not available. Individual discrete health states should be used for serious adverse reactions to treatment and the corresponding HSUVs sourced as normal. Care should be taken to avoid double counting when capturing the effects for both less severe adverse reactions (e.g. itchy skin rash or dry cough) and more severe adverse events (e.g. fatigue in oncology). Transparency in reporting standards for both the justification of the evidence used and any ‘adjustments’ is important to increase readers’ confidence that the evidence used is the most appropriate available.

Suggested Citation

  • Roberta Ara & John Brazier & Ismail Azzabi Zouraq, 2017. "The Use of Health State Utility Values in Decision Models," PharmacoEconomics, Springer, vol. 35(1), pages 77-88, December.
  • Handle: RePEc:spr:pharme:v:35:y:2017:i:1:d:10.1007_s40273-017-0550-0
    DOI: 10.1007/s40273-017-0550-0
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40273-017-0550-0
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.

    File URL: https://libkey.io/10.1007/s40273-017-0550-0?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. John Brazier & Jennifer Roberts & Aki Tsuchiya & Jan Busschbach, 2004. "A comparison of the EQ‐5D and SF‐6D across seven patient groups," Health Economics, John Wiley & Sons, Ltd., vol. 13(9), pages 873-884, September.
    2. Roberta Ara & Donna Rowen & Clara Mukuria, 2017. "The Use of Mapping to Estimate Health State Utility Values," PharmacoEconomics, Springer, vol. 35(1), pages 57-66, December.
    3. Peasgood, T & Ward, S & Brazier, J, 2010. "A review and meta-analysis of health state utility values in breast cancer," MPRA Paper 29950, University Library of Munich, Germany.
    4. repec:spr:pharme:v:26:y:2008:i:9:p:725-727 is not listed on IDEAS
    5. Roberta Ara & John Brazier, 2017. "Estimating Health State Utility Values for Comorbidities," PharmacoEconomics, Springer, vol. 35(1), pages 89-94, December.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Jonathan Karnon, 2017. "Heath State Utility Values for Cost-Effectiveness Models," PharmacoEconomics, Springer, vol. 35(1), pages 1-3, December.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. SeungJin Bae & SooOk Lee & Eun Bae & Sunmee Jang, 2013. "Korean Guidelines for Pharmacoeconomic Evaluation (Second and Updated Version)," PharmacoEconomics, Springer, vol. 31(4), pages 257-267, April.
    2. Aileen R. Neilson & Gareth T. Jones & Gary J. Macfarlane & Ejaz MI Pathan & Paul McNamee, 2022. "Generating EQ-5D-5L health utility scores from BASDAI and BASFI: a mapping study in patients with axial spondyloarthritis using longitudinal UK registry data," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 23(8), pages 1357-1369, November.
    3. Brazier, JE & Yang, Y & Tsuchiya, A, 2008. "A review of studies mapping (or cross walking) from non-preference based measures of health to generic preference-based measures," MPRA Paper 29808, University Library of Munich, Germany.
    4. Micah Rose & Stephen Rice & Dawn Craig, 2018. "Does Methodological Guidance Produce Consistency? A Review of Methodological Consistency in Breast Cancer Utility Value Measurement in NICE Single Technology Appraisals," PharmacoEconomics - Open, Springer, vol. 2(2), pages 97-107, June.
    5. Hirsch Ruchlin & Ralph Insinga, 2008. "A Review of Health-Utility Data for Osteoarthritis," PharmacoEconomics, Springer, vol. 26(11), pages 925-935, November.
    6. Tsuchiya, Aki & Brazier, John & Roberts, Jennifer, 2006. "Comparison of valuation methods used to generate the EQ-5D and the SF-6D value sets," Journal of Health Economics, Elsevier, vol. 25(2), pages 334-346, March.
    7. Feng Xie & Michael Zoratti & Kelvin Chan & Don Husereau & Murray Krahn & Oren Levine & Tammy Clifford & Holger Schunemann & Gordon Guyatt, 2019. "Toward a Centralized, Systematic Approach to the Identification, Appraisal, and Use of Health State Utility Values for Reimbursement Decision Making: Introducing the Health Utility Book (HUB)," Medical Decision Making, , vol. 39(4), pages 371-379, May.
    8. Ayse Kuspinar & Nancy Mayo, 2014. "A Review of the Psychometric Properties of Generic Utility Measures in Multiple Sclerosis," PharmacoEconomics, Springer, vol. 32(8), pages 759-773, August.
    9. Marco DiBonaventura & Lance Richard & Maya Kumar & Anna Forsythe & Natalia M Flores & Margaret Moline, 2015. "The Association between Insomnia and Insomnia Treatment Side Effects on Health Status, Work Productivity, and Healthcare Resource Use," PLOS ONE, Public Library of Science, vol. 10(10), pages 1-14, October.
    10. Efthymiadou, Olina & Mossman, Jean & Kanavos, Panos, 2019. "Health related quality of life aspects not captured by EQ-5D-5L: Results from an international survey of patients," Health Policy, Elsevier, vol. 123(2), pages 159-165.
    11. C. Rubio-Terrés & J. Soria & P. Morange & J. Souto & P. Suchon & J. Mateo & N. Saut & D. Rubio-Rodríguez & J. Sala & A. Gracia & S. Pich & E. Salas, 2015. "Economic Analysis of Thrombo inCode, a Clinical–Genetic Function for Assessing the Risk of Venous Thromboembolism," Applied Health Economics and Health Policy, Springer, vol. 13(2), pages 233-242, April.
    12. Marieke Krol & Elly Stolk & Werner Brouwer, 2014. "Predicting productivity based on EQ-5D: an explorative study," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(5), pages 465-475, June.
    13. Rowen, D & Brazier, J & Tsuchiya, A & Hernández, M & Ibbotson, R, 2009. "The simultaneous valuation of states from multiple instruments using ranking and VAS data: methods and preliminary results," MPRA Paper 29841, University Library of Munich, Germany.
    14. Dirk Müller & Marion Danner & Rita Schmutzler & Christoph Engel & Kirsten Wassermann & Björn Stollenwerk & Stephanie Stock & Kerstin Rhiem, 2019. "Economic modeling of risk-adapted screen-and-treat strategies in women at high risk for breast or ovarian cancer," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(5), pages 739-750, July.
    15. Matthew Franklin & Clara Mukuria & Brendan Mulhern & Irwin Tran & John Brazier & Stuart Watson, 2019. "Measuring the Burden of Schizophrenia Using Clinician and Patient-Reported Measures: An Exploratory Analysis of Construct Validity," The Patient: Patient-Centered Outcomes Research, Springer;International Academy of Health Preference Research, vol. 12(4), pages 405-417, August.
    16. David Feeny, 2012. "The Multi-attribute Utility Approach to Assessing Health-related Quality of Life," Chapters, in: Andrew M. Jones (ed.), The Elgar Companion to Health Economics, Second Edition, chapter 36, Edward Elgar Publishing.
    17. D. Stratmann‐Schoene & T. Kuehn & R. Kreienberg & R. Leidl, 2006. "A preference‐based index for the SF‐12," Health Economics, John Wiley & Sons, Ltd., vol. 15(6), pages 553-564, June.
    18. Patricia Blank & Martin Filipits & Peter Dubsky & Florian Gutzwiller & Michael Lux & Jan Brase & Karsten Weber & Margaretha Rudas & Richard Greil & Sibylle Loibl & Thomas Szucs & Ralf Kronenwett & Mat, 2015. "Cost-Effectiveness Analysis of Prognostic Gene Expression Signature-Based Stratification of Early Breast Cancer Patients," PharmacoEconomics, Springer, vol. 33(2), pages 179-190, February.
    19. Stavros Petrou & Christine Hockley, 2005. "An investigation into the empirical validity of the EQ‐5D and SF‐6D based on hypothetical preferences in a general population," Health Economics, John Wiley & Sons, Ltd., vol. 14(11), pages 1169-1189, November.
    20. Nasuh C. Büyükkaramikli & Saskia Groot & Rob Riemsma & Debra Fayter & Nigel Armstrong & Piet Portegijs & Steven Duffy & Jos Kleijnen & Maiwenn J. Al, 2019. "Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technol," PharmacoEconomics, Springer, vol. 37(2), pages 141-153, February.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:35:y:2017:i:1:d:10.1007_s40273-017-0550-0. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.